Board of Directors
Thomas Lönngren
Chairman
Degree in pharmacy and MSc in Social and Regulatory Pharmacy from Uppsala University.
Chairman since: April 2021
Number of shares in Egetis: 283,159
Born 1950.
Other assignments: Dr Lönngren serves as board member at Compass Pathways PLC, London UK and NDA Groupe, Sweden. He is Director at his own company PharmaExec Consulting AB and Strategic Advisor at the NDA Group, which he has done since 2010. He act as advisor to the following companies and organizations: Artis Venture, San Francisco, US, Baren Therapeutics, San Francisco US, Faculty member of GLG Institute (Gerson Lehrman Group), New York, US, Special advisor to the Centre for Innovation in Regulatory Science (CIRS), London UK, ScientificMed AB Stockholm, Sweden
Previous experience: Deputy General Director of the Swedish Medical Product Agency until 2000. 2001 until 2010, Mr. Lönngren served as the Executive Director of the European Medical Agency. He has held non-executive board positions in Cbio Ltd, Brisbane, Analytica Ltd, Brisbane and Global Kinetic Corporation Ltd, Melbourne Australia
Other: Honorary Member of the Royal Pharmaceutical Society of Great Britain, Honorary Fellow of the Royal College of Physicians in Great Britain, Honorary Doctorate from the University of Uppsala, Honorary Doctorate from University of Bath, UK
Independent in relation to the Company’s major shareholders and the Company and its management.
Thomas Lönngren Chairman
Mats Blom
Board Member
BA, Business Administration and Economics, University of Lund and MBA, IESE University of Navarra, Barcelona, Spain
Member of the Board since: April 2021
Number of shares in Egetis: 2,934,762
Born 1965
Other assignments: Currently serves as the CFO of NorthSea Therapeutics, Amsterdam, the Netherlands. Board member of Hansa Biopharma and Auris Medical
Previous experience: He has served as CFO of Zealand Pharma A/B, a biotechnology company dual listed at Nasdaq in New York and Copenhagen, and Swedish Orphan International, an orphan drug company acquired by BioVitrum in 2009. In addition, Mats has been CFO at Modus Therapeutics, Active Biotech AB and Anoto Group AB. He has also served as a management consultant at Gemini Consulting and Ernst & Young.
Independent in relation to the company’s major shareholders and the Company and its management.
Mats Blom Board Member
Gunilla Osswald
Board Member
Pharmacist and Ph.D. in biopharmacy and pharmacokinetics at Uppsala University, Sweden
Member of the Board since: 2017
Number of shares in Egetis: 0
Born: 1961.
Other current assignments: President and Chief Executive Officer Bioarctic. Board member of SpineMedical AB and deputy board member of LPB Sweden AB
Previous appointments: Board member of SP Process Development AB, SpineMedical Sverige AB and LPB Sweden Holding AB.
Independent in relation to the Company’s major shareholders and the Company and its management.
Gunilla Osswald Board Member
Elisabeth Svanberg
Board Member
MD and PhD from the University of Gothenburg, Sweden.
Member of the Board since: 2017
Number of shares in Egetis: 27 396
Born 1961.
Other appointments: Currently serves as associate professor of surgery and is serving as Chief Development Officer at Ixaltis SA since 2016 and Chief Medical Officer at Kuste Biopharma since 2020. Board member of Galapagos NV, Amolyt Pharma SAS and LEO Pharma A/S.
Previous appointments: Board member of the Swedish American Chamber of Commerce New York. Head of the Established Products Group at Janssen Pharmaceuticals 2014–2016. Leading the development of a novel diabetes medicine at Bristol Myers Squibb (BMS) in the US. Head of Medical Affairs for the Intercontinental region 2000–2007.
Independent in relation to the Company’s major shareholders and the Company and its management.
Elisabeth Svanberg Board Member
Peder Walberg
Board Member
MD and BSc in International Economics and Business Administration from Uppsala University
Member of the Board since: 2020
Number of shares in Egetis: 33.776.221 (via Cetoros AB)
Born: 1974
Other current assignments: Board of Immedica
Previous appointments: Peders background includes being the founder and CEO of Rare Thyroid Therapeutics and Medical Need Europe and co-founder of Wilson Therapeutics. Peder has also served as EVP Business Development and Strategy at Swedish Orphan and Sobi and Nordic Head of New Products and BD&L at Novartis. He has previously been a director of the board of Wilson Therapeutics and OxThera and has a background as a management consultant with the Boston Consulting Group.
Peder Walberg Board Member
